久久偷看各类wc女厕嘘嘘偷窃,国语对白农村老太婆bbw,久久婷婷五月综合色欧美,久久人与动人物a级毛片,久久久亚洲欧洲日产国码是av

Ly6k (E4K8Y) XP Rabbit mAb



商城價(jià): 登錄可見(jiàn)

品    牌:CST/賽信通

貨    號(hào):44263T

規(guī)    格:

運(yùn)費(fèi): 登錄后可查看運(yùn)費(fèi)

DeepBio得分:
DeepBio得分 是基于文獻(xiàn)引用次數(shù),影響因子,文獻(xiàn)新近度等因素計(jì)算的客觀產(chǎn)品評(píng)級(jí),得分越高表明該產(chǎn)品經(jīng)過(guò)越可靠的實(shí)驗(yàn)驗(yàn)證,質(zhì)量可信度越高
1家供應(yīng)商在售
商品名稱(chēng) 規(guī)格 代理級(jí)別 價(jià)格 運(yùn)費(fèi) 供應(yīng)商 購(gòu)買(mǎi)
Ly6k (E4K8Y) XP ? Rabbit mAb
交貨周期:現(xiàn)貨
20 μl 經(jīng)銷(xiāo)
登錄可見(jiàn)

-

北京敏泰元科技有限公司
庫(kù)存:20

  • 產(chǎn)品詳情

應(yīng)用:W, IP, IHC-Bond, IHC-P
Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).Ly6k is a member of the Ly6/urokinase type plasminogen activator receptor-like protein (uPAR)(LU) superfamily. It is expressed in testes where in interaction with another (uPAR)(LU) family member, TEX101, it is proposed to be necessary for the production of viable sperm (4). The human ortholog of this protein, LY6K, has been characterized to be a CTA. It is found to be upregulated in numerous types of cancer, including esophageal squamous cell carcinoma, bladder cancer, and breast cancer (5,6).

Supporting Data

REACTIVITY M
SENSITIVITY Endogenous
MW (kDa) 18
Source/Isotype Rabbit IgG

Application Key:

  • W-Western
  • IP-Immunoprecipitation
  • IHC-Immunohistochemistry
  • ChIP-Chromatin Immunoprecipitation
  • IF-Immunofluorescence
  • F-Flow Cytometry
  • E-P-ELISA-Peptide

Species Cross-Reactivity Key:

  • H-Human
  • M-Mouse
  • R-Rat
  • Hm-Hamster
  • Mk-Monkey
  • Vir-Virus
  • Mi-Mink
  • C-Chicken
  • Dm-D. melanogaster
  • X-Xenopus
  • Z-Zebrafish
  • B-Bovine
  • Dg-Dog
  • Pg-Pig
  • Sc-S. cerevisiae
  • Ce-C. elegans
  • Hr-Horse
  • All-All Species Expected

Product Usage Information

Application Dilution
Western Blotting 1:1000
Immunoprecipitation 1:200
IHC-Leica? Bond? 1:200 - 1:800
Immunohistochemistry (Paraffin) 1:200 - 1:800

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

Ly6k (E4K8Y) XP? Rabbit mAb recognizes endogenous levels of total Ly6k protein.

Species Reactivity:

Mouse

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro70 of murine Ly6k protein.

Background

Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).

Ly6k is a member of the Ly6/urokinase type plasminogen activator receptor-like protein (uPAR)(LU) superfamily. It is expressed in testes where in interaction with another (uPAR)(LU) family member, TEX101, it is proposed to be necessary for the production of viable sperm (4). The human ortholog of this protein, LY6K, has been characterized to be a CTA. It is found to be upregulated in numerous types of cancer, including esophageal squamous cell carcinoma, bladder cancer, and breast cancer (5,6).

  1. Caballero, O.L. and Chen, Y.T. (2009) Cancer Sci 100, 2014-21.
  2. De Smet, C. et al. (1999) Mol Cell Biol 19, 7327-35.
  3. Gjerstorff, M.F. et al. (2015) Oncotarget 6, 15772-87.
  4. Endo, S. et al. (2016) Sci Rep 6, 23616.
  5. Ishikawa, N. et al. (2007) Cancer Res 67, 11601-11.
  6. Kono, K. et al. (2009) Cancer Sci 100, 1502-9.

友情鏈接 :  中國(guó)科學(xué)院 國(guó)科控股 喀斯瑪控股有限公司 中科海外人才創(chuàng)業(yè)園

商城介紹 | 媒體報(bào)道 | 法規(guī)政策 | 協(xié)議專(zhuān)區(qū)

京公網(wǎng)安備 11010802025067號(hào) 增值電信業(yè)務(wù)經(jīng)營(yíng)許可證:京B2-20171454 ICP備案號(hào):京ICP備16050672號(hào)-1 喀斯瑪科技版權(quán)所有 2017-

藥品醫(yī)療器械網(wǎng)絡(luò)信息服務(wù)備案: (京)-網(wǎng)藥械信息備字(2022)第00393號(hào) 醫(yī)療器械網(wǎng)絡(luò)交易服務(wù)第三方平臺(tái)備案編號(hào):京網(wǎng)械平臺(tái)備字(2021)第00006號(hào)

網(wǎng)絡(luò)食品交易第三方平臺(tái)提供者備案 :京食藥網(wǎng)食備202110062 信息系統(tǒng)安全等級(jí)保護(hù)備案證明(三級(jí))